Erlotinib in Treating Patients With Barrett Esophagus
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming. Erlotinib
may keep esophageal cancer from forming in patients with Barrett esophagus by blocking some
of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with
Barrett esophagus.